Tilray Medical Expands Australian Medical Cannabis Offerings

NEW YORK – Tilray Medical, an internal division of Tilray Brands Inc., one of the largest global suppliers of pharmaceutical-grade medical Cannabis operating in 20 countries across five continents, announced expansion of its medical Cannabis portfolio in Australia since entering the market in 2017.

The company will introduce new items over the coming months under the Redecan and Good Supply brands. Redecan’s lineup will gain flower, extracts, vapes and pastilles. Good Supply will add fresh flower varieties focused on higher potency options. The changes are designed to give Australian prescribers and patients more choices within the Therapeutic Goods Administration’s regulated access system.

Tilray Medical has supplied EU-GMP certified Cannabis in Australia for several years through prescribers, pharmacies and clinics. The new rollout builds on earlier steps, including the 2025 arrival of Good Supply pastilles, and aligns with steady patient demand in the country. Industry data show Australia’s medical Cannabis market at roughly $793 million in 2025, with projections pointing to continued growth through the next decade.

Rajnish Ohri, president of international operations at Tilray Brands, said in the release:

“Australia represents an important strategic market within our international growth strategy. This launch reflects our long-term commitment to delivering quality, differentiated Cannabis products. By bringing together proven genetics, rigorous quality standards and our strong local market expertise, we are excited to support the needs of the Australian community. This milestone reflects our continued investment across priority global markets, as we broaden access to trusted cannabis products worldwide.”

Here, at Highly Capitalized Network-HCN, we see this move as a straightforward portfolio adjustment that matches Tilray’s pattern of incremental product additions in established medical markets. It gives patients practical format options without altering the regulatory framework or promising outsized shifts in market share and fits Tilray’s broader international supply focus, where consistent quality and local distribution remain the core requirements for sustained access.